文献速递胸部肿瘤

肺癌中核输出抑制的治疗靶向研究

Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-06-21

该综述阐述核质转运异常在肺癌中的致癌作用,聚焦选择性核输出抑制剂(SINE)靶向输出蛋白-1(XPO1)的策略。临床前及临床试验显示,XPO1抑制剂selinexor单药有抗肿瘤活性,联合方案有协同效应,主要毒性为低级别血细胞减少和胃肠道反应。SINE对KRAS驱动肿瘤可能特别相关,一项针对经治晚期KRAS突变非小细胞肺癌的多中心1/2期试验正在进行中。

要点

  • XPO1是多种抑癌蛋白和细胞周期调控因子的唯一输出蛋白,为SINE的主要开发靶点。
  • selinexor是研究最广泛的SINE,单药有抗癌活性,联合方案有协同效应,主要毒性为低级别血细胞减少和胃肠道反应。
  • SINE对KRAS驱动肿瘤可能特别相关,展示显著合成致死效应;一项经治晚期KRAS突变NSCLC的多中心1/2期试验正在进行。

核心结论

  • 靶向XPO1的SINE在临床前模型和人体临床试验中显示出抗肿瘤疗效,selinexor单药有抗癌活性,联合方案有协同效应。
  • SINE对KRAS驱动肿瘤可能特别相关,该策略展示显著合成致死效应。

研究设计与样本

  • 综述,总结SINE靶向核输出抑制在肺癌中的临床前与临床研究证据。
  • 提及一项在经治晚期KRAS突变NSCLC中进行的selinexor多中心1/2期临床试验正在进行中。

主要发现

  • 肿瘤抑制蛋白和细胞周期调控因子(包括视网膜母细胞瘤蛋白、腺瘤性息肉病 coli、p53、p73、p21、p27、叉头框O、信号转导和转录激活因子3、κB抑制因子、拓扑异构酶II和蛋白酶激活受体4)的核质转运异常导致肿瘤发生和凋亡失活。
  • XPO1是上述多种蛋白的唯一输出蛋白,是SINE开发的主要焦点。
  • selinexor(KPT-330,Karyopharm Therapeutics,Inc.,Newton Centre,MA)是研究最广泛的SINE,在多种癌症类型中显示单药抗癌活性和联合方案协同效应,主要毒性为低级别血细胞减少和胃肠道反应。
  • SINE对KRAS驱动肿瘤可能特别相关,该治疗策略展示显著合成致死效应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intracellular compartmentalization and trafficking of molecules plays a critical role in complex and essential cellular processes. In lung cancer and other malignancies, aberrant nucleocytoplasmic transport of tumor suppressor proteins and cell cycle regulators results in tumorigenesis and inactivation of apoptosis. Pharmacologic agents targeting this process, termed selective inhibitors of nuclear export (SINE), have demonstrated antitumor efficacy in preclinical models and human clinical trials. Exportin-1 (XPO1), which serves as the sole exporter of several tumor suppressor proteins and cell cycle regulators, including retinoblastoma, adenomatous polyposis coli, p53, p73, p21, p27, forkhead box O, signal transducer and activator of transcription 3, inhibitor of κB, topoisomerase II, and protease activated receptor 4-is the principal focus of development of SINE. The most extensively studied of the SINE to date, the exportin-1 inhibitor selinexor (KPT-330 [Karyopharm Therapeutics, Inc., Newton Centre, MA]), has demonstrated single-agent anticancer activity and synergistic effects in combination regimens against multiple cancer types, with principal toxicities of low-grade cytopenias and gastrointestinal effects. SINE may have particular relevance in KRAS-driven tumors, for which this treatment strategy demonstrates significant synthetic lethality. A multicenter phase 1/2 clinical trial of selinexor in previously treated advanced KRAS-mutant NSCLC is under way.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gupta A, Saltarski JM, White MA, et al. Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer. J Thorac Oncol. 2017. PMID: 28647672. doi:10.1016/j.jtho.2017.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。